Adam or someone should point out that "dystrophin as a marker for approval" is what we want to happen for our exon drugs beyond the first 3 or so. In other words we want those small population exon drugs to be granted approval by virtue of quick small trials - if those trials show the "necessary" amount of dystrophin being produced - about 20% or more. The "dystrophin as marker for approval" is a ways down the road. We are not going to be relying on it for this drug or the next 2 or 3. But after those 3 or 4 show the same corrrelation of, say, 20% dystrophin with a clinical benefit, that's when we want the dystrophin marker approval modality to kick in.